Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

10.4%

17 terminated/withdrawn out of 164 trials

Success Rate

85.2%

-1.3% vs industry average

Late-Stage Pipeline

32%

53 trials in Phase 3/4

Results Transparency

24%

24 of 98 completed trials have results

Key Signals

11 recruiting24 with results10 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 2
50(37.6%)
Phase 3
28(21.1%)
Phase 4
25(18.8%)
N/A
15(11.3%)
Phase 1
15(11.3%)
133Total
Phase 2(50)
Phase 3(28)
Phase 4(25)
N/A(15)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (164)

Showing 20 of 164 trials
NCT05289687Phase 2Recruiting

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Role: collaborator

NCT04354233Not ApplicableCompleted

A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer

Role: collaborator

NCT04166565Phase 2Active Not Recruiting

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

Role: collaborator

NCT02436707Phase 2Active Not Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Role: collaborator

NCT02160353Phase 2Completed

Neo-adjuvant Abiraterone Prostate Study

Role: collaborator

NCT06392841Phase 2Withdrawn

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Role: collaborator

NCT06355986Not ApplicableNot Yet Recruiting

Computerized Decision Support to Prevent Stroke in Atrial Fibrillation

Role: collaborator

NCT01760005Phase 2Active Not Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Role: collaborator

NCT04113018Phase 2Active Not Recruiting

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT05918666Active Not Recruiting

National Register of Actionable Mutations

Role: collaborator

NCT06237803Recruiting

European Myeloma Network (EMN) Sample Project

Role: collaborator

NCT03734198Phase 2Active Not Recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Role: collaborator

NCT06483139Recruiting

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Role: collaborator

NCT01592370Phase 1Completed

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Role: collaborator

NCT03590652Phase 2Terminated

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT06114628Phase 2Recruiting

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Role: collaborator

NCT05299125Phase 2Active Not Recruiting

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Role: collaborator

NCT06046287Phase 2Withdrawn

Daratumumab for Polyneuropathy Associated With MGUS

Role: collaborator

NCT06527690Phase 2Withdrawn

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Role: collaborator

NCT01793103Active Not Recruiting

Brigham and Women's Rheumatoid Arthritis Sequential Study

Role: collaborator